For healthcare-associated pneumonia, which intravenous regimen is listed?

• A. IV Ceftriaxone + Doxycycline
• B. IV Piperacillin-Tazobactam
• C. IV Cefepime + Levofloxacin
• D. Oral Amoxicillin

Answer: (C)

In healthcare-associated pneumonia, you want IV antibiotics with strong, broad-spectrum activity against gram-negatives, including Pseudomonas, because MDR organisms are common in hospital settings. Cefepime is a fourth-generation cephalosporin with solid antipseudomonal and gram-negative coverage. Levofloxacin adds further activity against Pseudomonas and also covers atypicals, giving a wider net of coverage when treating serious hospital-acquired infections. Using them together as an IV regimen provides broad, potent therapy suitable for the greater pathogen diversity seen in healthcare-associated pneumonia, especially when resistance is a concern or local guidelines support combination therapy. The other options are less appropriate for this context: the ceftriaxone–doxycycline combo lacks reliable antipseudomonal coverage and relies on doxycycline, which is not ideal for HAP; an oral antibiotic isn’t suitable for a hospital-acquired infection requiring IV therapy; and while piperacillin-tazobactam is a valid IV regimen, the question’s listed combination with cefepime and levofloxacin represents the broader IV coverage emphasized for HAP management.